Sumoja

Sumoja is an early-stage biotechnology company focused on developing novel therapeutics that target the SUMOylation pathway, a critical post-translational modification process. Founded by pioneers in the field of protein degradation and modification, including Alfred Goldberg, Daniel Finley, and Wade Harper, the company leverages deep expertise in the SUMO (Small Ubiquitin-like Modifier) system to address unmet needs in oncology and neurodegeneration. Sumoja's platform aims to discover and develop small molecule modulators that can precisely regulate protein function and stability by influencing SUMO attachment. The company operates primarily in a stealth or early-development mode within the vibrant Cambridge biotech ecosystem.